Search company, investor...

Predict your next investment

Venture Capital
brandoncapital.vc

Investments

64

Portfolio Exits

5

Funds

7

Partners & Customers

1

About Brandon Capital

Brandon Capital Partners makes seed and venture capital investments to support the development and international growth of Australian life science companies. The firm works collaboratively with entrepreneurs to demonstrate the benefit of their technology, thereby creating value for them, their teams and investors.

Headquarters Location

Level 1 257 Collins Street

Melbourne, Victoria, 3000,

Australia

+61 3 9657 0700

Want to inform investors similar to Brandon Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Brandon Capital News

Aravax raises $20M series B round to take peanut allergy immunotherapy to phase II

Dec 27, 2022

Dec. 27, 2022 With $20 million raised in a series B round led by Brandon Capital and Tenmile, Aravax Pty Ltd. is poised to begin phase II trials of its immunotherapy, PVX-108, for peanut allergy. “Our product is unlike other approaches that are in later stages of development, and those products generally use natural extracts from peanuts to treat peanut allergy,” Aravax CEO Pascal Hickey told BioWorld.

Brandon Capital Investments

64 Investments

Brandon Capital has made 64 investments. Their latest investment was in Aravax as part of their Series B on December 12, 2022.

CBI Logo

Brandon Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/19/2022

Series B

Aravax

$20M

No

5

12/6/2022

Series A

Entact Bio

$81M

Yes

11

11/22/2022

Series C

CatalYm

$51M

Yes

16

11/9/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

9/28/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/19/2022

12/6/2022

11/22/2022

11/9/2022

9/28/2022

Round

Series B

Series A

Series C

Series A

Series A

Company

Aravax

Entact Bio

CatalYm

Subscribe to see more

Subscribe to see more

Amount

$20M

$81M

$51M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

11

16

10

10

Brandon Capital Portfolio Exits

5 Portfolio Exits

Brandon Capital has 5 portfolio exits. Their latest portfolio exit was EBR Systems on November 24, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/24/2021

IPO

$99M

Public

2

3/15/2019

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

2/7/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/29/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/17/2012

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/24/2021

3/15/2019

2/7/2018

6/29/2015

4/17/2012

Exit

IPO

Spinoff / Spinout

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Brandon Capital Fund History

7 Fund Histories

Brandon Capital has 7 funds, including MRCF5.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/29/2019

MRCF5

$147.67M

2

7/26/2016

Medical Research Commercialization Fund III

$99M

10

5/20/2015

Medical Research Commercialisation Fund III

Subscribe to see more

Subscribe to see more

$99M

10

6/30/2012

MRCF IIF Partnership LP

Subscribe to see more

Subscribe to see more

$99M

10

6/30/2009

Brandon Biosciences Fund No 1

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/29/2019

7/26/2016

5/20/2015

6/30/2012

6/30/2009

Fund

MRCF5

Medical Research Commercialization Fund III

Medical Research Commercialisation Fund III

MRCF IIF Partnership LP

Brandon Biosciences Fund No 1

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$147.67M

$99M

$99M

$99M

$99M

Sources

2

10

10

10

10

Brandon Capital Partners & Customers

1 Partners and customers

Brandon Capital has 1 strategic partners and customers. Brandon Capital recently partnered with COPD Foundation on February 2, 2022.

Brandon Capital Team

5 Team Members

Brandon Capital has 5 team members, including current Founder, Managing Director, Stephen Thompson.

Name

Work History

Title

Status

Stephen Thompson

Terra Rossa Capital, Apax Partners, and Cantab Pharmaceuticals

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Stephen Thompson

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Terra Rossa Capital, Apax Partners, and Cantab Pharmaceuticals

Title

Founder, Managing Director

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.